A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels

August 5, 2026 updated by: Artah Nutrition Limited

This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. The trial is a single-arm, unblinded, virtual study in which all 50 participants will use the test product daily for 4 weeks.

Participants will complete self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4, and will undergo cognitive battery testing at Baseline and Week 4. The primary endpoint is change in cognitive performance scores as measured by a standardized cognitive battery. Secondary endpoints include participants' self-reported perceptions of mental clarity, alertness, mood, physical performance, overall energy levels, and frequency of food cravings.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Nevada
      • Las Vegas, Nevada, United States, 89101
        • Citruslabs

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Be male or female.
  • Be aged 25-60.
  • Anyone currently experiencing mild to moderate issues with at least three of the following: low energy or fatigue
  • difficulty concentrating or low mental sharpness
  • experiences of brain fog or lack of mental clarity
  • feeling of low productivity
  • muscle weakness
  • unwanted food cravings.
  • Undertakes moderate to high-intensity exercise such as jogging/running and/or heavy resistance training at least three times per week.
  • Willing to refrain from taking any products, medications, or supplements that target energy, cognition, or physical performance during the test period.
  • Anyone with a BMI 18.5 to 30.
  • Anyone who has access to a device (e.g., smartphone, laptop, computer) for reliable internet.
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • Anyone willing to maintain a consistent diet and physical activity throughout study duration.

Exclusion Criteria:

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Anyone suffering from gastrointestinal disorders including but not limited to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and celiac disease.
  • Anyone suffering from hyperkalemia (high potassium), liver disease, or kidney disease.
  • Anyone taking ACE inhibitors or potassium-sparing diuretics, examples include: Spironolactone (Aldactone), Eplerenone (Inspra), Amiloride (Midamor), Triamterene (Maxzide), Lisinopril (Zestril, Prinivil), Enalapril (Vasotec), Ramipril (Altace), Benazepril (Lotensin), Quinapril (Accupril), Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), Lithium carbonate (Lithobid, Eskalith).
  • Anyone taking antibiotics.
  • Anyone with any allergies or sensitivities to any of the study product ingredients.
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
  • Anyone unwilling to follow the study protocol.
  • Anyone with a history of substance abuse.
  • Anyone who is a shift worker with an irregular sleep-wake cycle.
  • Anyone who drinks heavily (8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
  • Anyone who is currently a smoker or has been a smoker in the past 3 months.
  • Currently partaking in another research study, or planning to at any point during this study's duration.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Cellular Hydration Supplement
Dietary supplement: Cellular Hydration Supplement
All 50 participants receive the Artah Cellular Hydration electrolyte supplement taken twice daily (once in the morning before the first meal and once in the afternoon after lunch or before evening exercise) as one teaspoon (approximately 7 g) stirred into 750 ml of water for 4 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Cognitive Battery Test Score (Polygons)
Time Frame: Baseline and Week 4
Change in processing speed and information sorting ability assessed via the Polygons timed cognitive battery subtest
Baseline and Week 4
Change in Cognitive Battery Test Score (Double Trouble)
Time Frame: Baseline and Week 4
Change in selective attention and processing speed assessed via the Double Trouble timed cognitive battery subtest (Stroop-based)
Baseline and Week 4
Change in Cognitive Battery Test Score (Feature Match)
Time Frame: Baseline and Week 4
Change in focus and processing speed assessed via the Feature Match timed cognitive battery subtest
Baseline and Week 4
Change in Cognitive Battery Test Score (Paired Associates)
Time Frame: Baseline and Week 4
Change in memory recall assessed via the Paired Associates performance-based cognitive battery subtest
Baseline and Week 4
Change in Cognitive Battery Test Score (Digit Span)
Time Frame: Baseline and Week 4
Change in short-term memory and cognitive flexibility assessed via the Digit Span performance-based cognitive battery subtest
Baseline and Week 4
Change in Cognitive Battery Test Score (Spatial Planning)
Time Frame: Baseline and Week 4
Change in executive function and logical decision-making assessed via the Spatial Planning timed cognitive battery subtest
Baseline and Week 4

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Self-Reported Mental Clarity and Focus
Time Frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Alertness
Time Frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Mood
Time Frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Physical Performance
Time Frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Overall Energy Levels
Time Frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Frequency of Food Cravings
Time Frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Artah Nutrition Limited

Collaborators

Citruslabs

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 13, 2025

Primary Completion (Actual)

August 16, 2025

Study Completion (Actual)

August 16, 2025

Study Registration Dates

First Submitted

August 5, 2026

First Submitted That Met QC Criteria

August 5, 2026

First Posted (Actual)

August 10, 2026

Study Record Updates

Last Update Posted (Actual)

August 10, 2026

Last Update Submitted That Met QC Criteria

August 5, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20772
  • legacy-20772

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe